住院患者使用利奈唑胺致贫血的相关危险因素

doi:10.3969/j.issn.2095-9400.2019.12.009

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1534 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨住院患者使用利奈唑胺（LZD）治疗期间发生贫血不良反应的相关危险因素。方法：采用回顾性研究，收集2012年5月至2017年5月温州医科大学附属第一医院接受LZD治疗且监测血药浓度的161例住院患者的临床资料，采用logistic回归分析LZD诱发贫血不良反应的相关危险因素。结果：31例（占19.2%）患者被评估为LZD相关性贫血，LZD治疗期间，中重度肾功能不全患者[GFR＜60 mL·（min·1.73 m2）-1]（OR=3.47，95%CI：1.49～8.13，P=0.004）以及药物谷浓度≥7 mg·L-1（OR=2.87，95%CI：1.11～6.93，P=0.024）者发生相关性贫血风险更高。结论：LZD相关性贫血与肾功能及体内药物浓度密切相关。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	戴映
	蒋淑莹
	余旭奔
	张春红
	胡卢丰
	林观样

关键词 ：利奈唑胺, 贫血, 血药浓度, 肾功能不全, 危险因素

Abstract：Objective: To investigate the factors affecting linezolid-induced anemia in hospitalized patients.Methods: A retrospective study was performed to collect data in 161 adult inpatients who received linezolid between May 2012 to May 2017. The risk factors of linezolid-related anemia were confirmed by univariate and multivariate logistic regression. Results: Of all the patients enrolled, linezolid-induced anemia developed in 31 (19.2%) patients during therapy. The incidence of anemia occurred more frequently in patients who received linezolid at concentration≥7 mg·L-1 (OR=2.87, 95%CI: 1.11-6.93, P=0.024) and those with moderate-severe renal impairment [GFR<60 mL·(min·1.73 m2)-1] (OR=3.47, 95%CI: 1.49-8.13, P=0.004). Conclusion: The results of our study indicated that high plasma linezolid concentration and renal impairment significantly affected the development of linezolid-induced anemia.

Key words： linezolid anemia plasma concentration renal insufficiency risk factor

收稿日期: 2019-09-06

基金资助:温州市科技局公益性社会发展（医疗卫生）项目（Y2017 0694）；浙江省药学会医院药学专项科研项目（2018ZYY42）。

通讯作者: 林观样，主任药师，Email：13867702133@163.com。

作者简介: 戴映（1988-），女，浙江温州人，药师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/10.3969/j.issn.2095-9400.2019.12.009 或 https://xb.wmu.edu.cn/CN/Y2019/V49/I12/900

[1] HERNÁNDEZ J, SERRANO DE LUCAS L, BAZA B, et al.
GRP-110 linezolid adverse reactions. A One Year Overview [J]. Eur J Hosp Pharm, 2013, 20(Suppl1): A40.
[2] MORAZAL, LEACHE L, AQUERRETA I, et al. Linezolid-induced haematological toxicity[J]. Farm Hosp, 2015, 39(6): 320-326.
[3] HANAI Y, MATSUO K, OGAWA M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia[J]. J Infect Chemother, 2016, 22(8): 536-542.
[4] HIRAKI Y, TSUJI Y, MATSUMOTO K, et al. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin[J]. Am J Med Sci, 2011, 342(6): 456-460.
[5] CATTANEO D, ALFFENAAR J W, NEELY M. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones[J]. Expert Opin Drug Metab Toxicol, 2016, 12(5): 533-544.
[6] FLANAGAN S, MCKEE E E, DAS D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function[J]. Antimicrob Agents Chemother, 2015, 59(1): 178-185.
[7] MINSON Q, GENTRY C A. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center[J]. Pharmacotherapy, 2010, 30(9): 895-903.
[8] LUO Z, XUN, WANG Y, et al. Linezolid-induced pure red cell aplasia: a case report and literature review[J]. J Int Med Res, 2018, 46(11): 4837-4844.
[9] WU V C, Wang Y T, Wang C Y, et al. High frequency of linezolid associated thrombocytopenia and anemia among patients with end-stage renal disease[J]. Clin Infect Dis, 2006, 42(1): 66-72.
[10] CATTANEO D, ORLANDO G, COZZI V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infec-tions[J]. Int J Antimicrob Agents, 2013, 41(6): 586-589.
[11] ZOLLER M, MAIER B, HORNUSS C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study[J]. Crit Care, 2014, 18(4): R148.
[12] NATSUMOTOB, YOKOTA K, OMATA F, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients[J]. Infection, 2014, 42(6): 1007-1012.
[13] CRASS R L, COJUTTI P G, PAI M P, et al. Reappraisal of linezolid dosing in renal impairment to improve safety[J]. Antimicrob Agents Chemother, 2019, 63(8). Doi: 10.1128/aac.00605-19.
[14] PEA F, VIALE P, COJUTTI P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients[J]. J Antimicrob Chemother, 2012, 67(8): 2034-2042.
[15] NUKUI Y, HATAKEYAMA S, OKAMOTO K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia [J]. J Antimicrob Chemother, 2013, 68(9): 2128-2133.
[16] BOAK L M, RAYNER C R, GRAYSON M L, et al. Clinical population pharmacokinetics and toxicodynamics of line-zolid[J]. Antimicrob Agents Chemother, 2014, 58(4): 2334-2343.
[17] PEA F, COJUTTI P G, BARALDO M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?[J]. Basic Clin Pharmacol Toxicol, 2017, 121(4): 303-308.
[18] MATSUMOTO K, SHIGEMI A, TAKESHITA A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult pa-tients[J]. Int J Antimicrob Agents, 2014, 44(3): 242-247.
[19] PEA F, COJUTTI P, PAGOTTO A, et al. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy[J]. Antimicrob Agents Chemother, 2012, 56(6): 3438-3440
[20] TAUBERT M, ZOLLER M, MAIER B, et al. Predictors of inadequate linezolid concentrations after standard dosing in critically Ill patient[J]. Antimicrob Agents Chemother, 2016, 60(9): 5254-5261.